Since SLC3A2 is degraded upon lorlatinib treatment in ALK-addicted NB cells (Fig. 1C, D), we investigated whether intracellular polyamine and BCAA concentrations were affected in response to ALK inhibition. This evidence concerns the gene SLC3A2 and neuroblastoma.